ArticleJournal of hospital medicine2025
Things We Do for No Reason™: Failing to consider primary aldosteronism in the initial evaluation of hypertension, hypertensive urgency, and hypertensive emergency.
Article in Journal of hospital medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hypertension and primary aldosteronism diagnosis in hospitalized patients: an observation from public hospitals in Victoria, Australia.Endocrine · 2026Observational
- Things We Do for No Reason™: Failing to consider primary aldosteronism in the initial evaluation of hypertension, hypertensive urgency, and hypertensive emergency.Journal of hospital medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is frequently treated as essential hypertension. However, secondary causes of hypertension should be considered, because distinct treatments are used for different causes of hypertension. Primary aldosteronism is considered a candidate for the most common cause of secondary hypertension. Despite the effects of many antihypertensive agents on the renin-angiotensin-aldosterone system, ongoing efforts to manage hypertension should not be discontinued solely for the purposes of screening. If a patient presents with new or untreated hypertension, screening should be considered before starting antihypertensive agents that could affect the renin-angiotensin-aldosterone system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.